Cataplexy: Symptoms, Narcolepsy Link, Diagnosis & Treatment Options

Cataplexy is a sudden, brief (<2 minutes), bilateral loss of muscle tone with preserved consciousness, triggered by strong emotions such as laughter, surprise, anger, or excitement. It is pathognomonic for narcolepsy type 1 (NT1) (narcolepsy with cataplexy), caused by the loss of hypothalamic orexin/hypocretin neurons.

Clinical Spectrum

Severity	Manifestations
Partial	Jaw sag, head nod, slurred speech, facial twitching, knee buckling, hand dropping objects
Complete	Full body collapse to ground; may last seconds to minutes
Status cataplecticus	Repeated attacks over hours (rare; often medication withdrawal or infection trigger)

Diagnostic Criteria (ICSD-3)

• NT1: Excessive daytime sleepiness (EDS) ≥3 months + cataplexy (≥1 episode) + CSF hypocretin-1 <110 pg/mL or <1/3 mean control OR MSLT: mean sleep latency ≤8 min + ≥2 SOREMPs
• NT2: EDS + MSLT criteria but no cataplexy and normal hypocretin

Differential Diagnosis

• Syncope: Loss of consciousness, pallor, bradycardia, no emotional trigger
• Drop attacks (vestibular, atonic seizure): No emotional trigger; may have loss of consciousness
• Pseudocataplexy (conversion): Inconsistent, prolonged, non-emotional triggers, suggestibility
• Paroxysmal kinesigenic dyskinesia: Movement-triggered, not emotion

Treatment

Agent	Mechanism	Dose Range	Notes
Sodium oxybate (Xyrem, Lumryz)	GABA-B agonist; consolidates sleep, reduces cataplexy	4.5–9 g/night divided	Gold standard for cataplexy; REMS program; improves EDS
Venlafaxine (SNRI)	NE/5-HT reuptake inhibition → ↑ monoamines in LC/PPT	37.5–225 mg/day	First-line off-label; rapid onset; withdrawal → rebound cataplexy
Fluoxetine / other SSRIs	5-HT reuptake inhibition	20–60 mg/day	Less effective than SNRIs; longer half-life = less withdrawal risk
Clomipramine (TCA)	Potent NE/5-HT reuptake inhibition	25–75 mg/day	Most potent anticataplectic; anticholinergic side effects
Pitolisant (Wakix)	H3 inverse agonist → ↑ histamine, ↑ orexin (if neurons remain)	17.8–35.6 mg AM	Approved for EDS + cataplexy in NT1; no abuse potential
Solriamfetol (Sunosi)	DA/NE reuptake inhibitor	75–150 mg AM	EDS only; minimal cataplexy effect

Non-Pharmacologic Management

• Scheduled naps (15–20 min ×1–2/day)
• Trigger awareness & avoidance (when safe)
• Safety precautions: avoid heights, swimming alone, operating machinery during high-risk periods
• Education of family, employers, teachers
• Support groups: Narcolepsy Network, Wake Up Narcolepsy

Key Point

Cataplexy is not a seizure or fainting. It is a dissociated REM sleep phenomenon (atonia intruding into wakefulness). Recognition enables specific treatment that dramatically improves safety and quality of life.